新发急性低氧性呼吸衰竭患者呼吸困难严重且与更高插管率相关
该研究为多中心随机对照试验的二次分析,纳入310例中259例测量了呼吸困难视觉模拟评分(VAS 0-100 mm)。基线呼吸困难VAS中位数46 mm(IQR 16-65),56%患者≥40 mm,插管率45%,90天死亡率20%。校正竞争风险模型显示,基线中度(VAS 40-64 mm)和重度(VAS≥65 mm)呼吸困难、收缩压、心率和PaO2/FiO2与插管独立相关(sHR分别为1.96和2.61,p=0.023;2.56,p<0.001;1.94,p=0.02;0.34,p=0.028)。基线VAS≥40 mm患者累积生存概率更低(logrank p=0.049)。
要点
- 基线呼吸困难VAS中位数46 mm(IQR 16-65),146例(56%)VAS≥40 mm,插管率45%,90天死亡率20%。
- 基线中度(VAS 40-64 mm)和重度(VAS≥65 mm)呼吸困难与插管独立相关(sHR 1.96和2.61,p=0.023)。
- 收缩压(sHR 2.56,p<0.001)、心率(sHR 1.94,p=0.02)和PaO2/FiO2(sHR 0.34,p=0.028)与插管独立相关。
- 基线VAS≥40 mm患者累积生存概率更低(logrank检验,p=0.049)。
- 90天死亡独立相关因素:SAPS 2≥25(p<0.001)、基线中重度呼吸困难(p=0.073)、PaO2/FiO2(p=0.118)和治疗分组(p=0.046)。
适用人群与场景
- 因新发急性低氧性呼吸衰竭入住ICU的患者,为多中心随机对照试验的二次分析人群。
诊断标准与关键阈值
- 呼吸困难采用视觉模拟评分(dyspnea-VAS)量化,范围0至100 mm;基线VAS≥40 mm定义为中重度呼吸困难,其中40-64 mm为中度,≥65 mm为重度。
研究设计与关键结果
- 多中心随机对照试验的二次分析,259例(共310例)测量了基线呼吸困难VAS;基线VAS中位数46 mm(IQR 16-65),146例(56%)VAS≥40 mm,插管率45%,90天死亡率20%。
- 竞争风险模型(考虑ICU转出)显示,与插管独立相关的基线因素包括:中度呼吸困难(VAS 40-64 mm)sHR 1.96、重度呼吸困难(VAS≥65 mm)sHR 2.61,p=0.023;收缩压sHR 2.56,p<0.001;心率sHR 1.94,p=0.02;PaO2/FiO2 sHR 0.34,p=0.028。
- 基线VAS≥40 mm患者累积生存概率更低(logrank检验,p=0.049)。
- Cox模型显示,与90天死亡独立相关的因素包括:SAPS 2≥25(p<0.001)、基线中重度呼吸困难(p=0.073)、PaO2/FiO2(p=0.118)和治疗分组(p=0.046)。
证据类型、等级与局限
- 证据类型:多中心随机对照试验的二次分析(原文标注为secondary analysis of a multicenter, randomized, controlled trial)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在因新发急性低氧性呼吸衰竭入住ICU的患者中,基线呼吸困难VAS≥40 mm(尤其是≥65 mm)与更高的插管风险和更高的死亡率相关,提示临床可关注呼吸困难的严重程度。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Dyspnea is a key symptom of de novo acute hypoxemic respiratory failure. This study explores dyspnea and its association with intubation and mortality in this population.
METHODS: This was a secondary analysis of a multicenter, randomized, controlled trial. Dyspnea was quantified by a visual analog scale (dyspnea-VAS) from zero to 100 mm. Dyspnea was measured in 259 of the 310 patients included. Factors associated with intubation were assessed with a competing risks model taking into account ICU discharge. The Cox model was used to evaluate factors associated with 90-day mortality.
RESULTS: At baseline (randomization in the parent trial), median dyspnea-VAS was 46 (interquartile range, 16-65) mm and was ≥ 40 mm in 146 patients (56%). The intubation rate was 45%. Baseline variables independently associated with intubation were moderate (dyspnea-VAS 40-64 mm) and severe (dyspnea-VAS ≥ 65 mm) dyspnea at baseline (sHR 1.96 and 2.61, p = 0.023), systolic arterial pressure (sHR 2.56, p < 0.001), heart rate (sHR 1.94, p = 0.02) and PaO2/FiO2 (sHR 0.34, p = 0.028). 90-day mortality was 20%. The cumulative probability of survival was lower in patients with baseline dyspnea-VAS ≥ 40 mm (logrank test, p = 0.049). Variables independently associated with mortality were SAPS 2 ≥ 25 (p < 0.001), moderate-to-severe dyspnea at baseline (p = 0.073), PaO2/FiO2 (p = 0.118), and treatment arm (p = 0.046).
CONCLUSIONS: In patients admitted to the ICU for de novo acute hypoxemic respiratory failure, dyspnea is associated with a higher risk of intubation and with a higher mortality.
TRIAL REGISTRATION: clinicaltrials.gov Identifier # NCT01320384.
参考来源
- Demoule A, Baptiste A, Thille AW, et al. Dyspnea is severe and associated with a higher intubation rate in de novo acute hypoxemic respiratory failure. Crit Care. 2024. PMID: 38783367. doi:10.1186/s13054-024-04903-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。